Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

Clinical trial NCT04592913 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04592913
Sponsor: AstraZeneca
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Gastrointestinal Neoplasms Esophagogastric Junction

Start date: 2020-11-17
Primary completion: 2024-12-20
Enrollment: 957

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.